In the early stages of human embryogenesis, a transcription factor called Twist1 plays a key regulatory role in how the embryo assumes form and function. Much later in life, however, researchers at the University of California, San Diego School of Medicine, say Twist1 can re-emerge, taking a darker and more deadly turn.
In a paper published in the March 15, 2011 issue of Cancer Cell, UCSD scientists led by Jing Yang, PhD, assistant professor of pharmacology and pediatrics, identify a unique function of Twist1 in later life: it promotes the formation of invadopodia in tumor cells, a vital step in the spread of such cells (metastasis) to surrounding tissues and other parts of the body.
Invadopodia (meaning "invasive feet") are tiny protrusions of tumor cells that extend into the extracellular matrix -- the surrounding connective tissue and fibers that provide support. Invadopodia concentrate enzymes that degrade the matrix so that tumor cells can break away and metastasize.
Previous studies have linked the expression of Twist1 to many aggressive, solid-tumor cancers, including melanomas, neuroblastomas, as well as breast and prostate cancer. The new research by Yang and colleagues describes in detail how Twist1 initiates the multi-step pathway resulting in invadopodia formation and matrix degradation. The research also reveals places in the process that may present potential targets for future anti-metastasis therapies.
After embryogenesis, Twist1 is normally suppressed. Cancer cells, however, reactivate the transcription factor, enabling Twist1 to initiate its complex pathway leading to metastasis. Drug designers, however, have yet to successfully devise a way to directly inhibit transcription factors like Twist1. The UCSD study points to other possibilities.
"We hope to inhibit downstream targets of Twist1 (such as platelet-derived growth factor receptors) to inhibit invadopodia formation and function," Yan
|Contact: Scott LaFee|
University of California - San Diego